Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This pharmacological intervention consists of a combination of **triamcinolone hexacetonide**, a potent synthetic glucocorticoid, and **lidocaine**, a local anesthetic. Triamcinolone hexacetonide is utilized for its long-acting anti-inflammatory and immunosuppressive properties, which help reduce tissue swelling and pain at the site of injection. Lidocaine provides immediate, short-term analgesia by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. In the context of clinical research at **Aalborg University**, this combination is administered via ultrasound-guided injection to the calcaneal insertion of the plantar fascia. It is being evaluated as part of a multimodal treatment strategy for **plantar fasciopathy**, often combined with heavy-slow resistance training (HSR) to address both immediate pain relief and long-term structural rehabilitation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone hexacetonide + lidocaine.